3D Tissue Models

Profile Details
Mollie Roth

Diaceutics, Inc.
Corporate Counsel, Vice President Business Development

, US
Phone: 202-280-5887
My Blogs:
My Twitter Hashtags:
Age: 50-55
Mollie Roth is Corporate Counsel and Vice President of Business Development for Diaceutics, an international change management and consulting firm specializing in personalized medicine that provides pharmaceutical industry leaders with the foundation and operational structure needed to effectively develop and commercialize targeted therapies to optimize overall return on investment. In her role at Diaceutics, Ms. Roth combines over ten years of experience in complex patent and product liability litigation for the pharmaceutical industry with her background as a research scientist to focus on the pharmacolegal and regulatory environment surrounding the personalized medicine industry and its evolving business dynamic. Prior to joining Diaceutics, Ms Roth was a member of the litigation and life sciences groups at Kaye Scholer in New York City and then Nixon Peabody in Washington, D.C. Prior to attending law school, Ms. Roth ran a research laboratory at Oregon State University’s College of Pharmacy focused on the role of amino acids in the body’s regulation and mediation of pain. Ms. Roth holds a B.A. in neuropsychopharmacology from Rutgers University and a J.D. from Vermont Law School and is expected to complete this year her L.LM in Biotechnology and Genomics at the Sandra Day O’Connor College of Law at Arizona State University, where she has also been a Visiting Faculty Fellow in the Center for the Study of Law, Science, & Technology.
Cancer Immunotherapy, personalized medicine, co-development of tests and drugs, business models of PM
Presented at Events Covering:
, Cancer Biology, Cell Biology, Drug Design, Genomics
Areas of Interest:
Personalized Medicine, pharmacogenomics, law
General Comments:
BSN Rank: 2795 / 3501 (What's this?)
Accomplish Score: 33
Popularity Score: Unavailable
# in My Circle: 0
# in My Org(s): 2
We'll Post Your CV for Free!
Speaking/Presenting-Abstract/Poster at Mtg: 2 (26 / 0)
Honors and Awards: 0 (0 / 0)
Clinical Trial Activity: 0 (0 / 0)
Grant Support: 0 (0 / 0)
Patents Pending: 0 (0 / 0)
Journal - Editor/Reviewer: 0 (0 / 0)
Peer Reviewed Papers, Books, Chapters: 2 (12 / 0)
  • The Warfarin Revised Package Insert: Is the Information in the Label Too Thin? (2009)
  • Identification and quantification of somatic alterations in plasma-derived, circulating tumor DNA (ctDNA) is gaining traction as a non-invasive and cost effective method of disease monitoring in cancer patients, particularly to evaluate response to treatment and monitor for disease recurrence. ()
Pre/Non Reviewed Papers, Proceedings: 0 (0 / 0)
Membership in Professional Societies: 0 (0 / 0)
White Papers: 0 (0 / 0)
Registered on BiotechScienceNews: 1

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.